GSK Pharma closes trading window from Oct 1 ahead of Q2FY27 results

0 min read | Published on 25 Sept 2026, 02:44 PM |Updated on 25 Sept 2026, 02:44 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

Trading window closed from October 1, 2026
Window reopens 48 hours after Q2FY27 results
Closure complies with SEBI insider trading rules
Board meeting date for results to be announced later

*this image is generated using AI for illustrative purposes only.

GlaxoSmithKline Pharmaceuticals Limited has closed its trading window for buying or selling shares effective Thursday, October 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the upcoming quarterly results.

The trading period will remain closed until 48 hours after the announcement of the un-audited financial results for the second quarter and half year ended September 30, 2026. This measure prevents insider trading during the sensitive period preceding the public disclosure of financial performance.

Board meeting date to be announced

The company stated that the specific date for the board meeting to declare the un-audited financial results for Q2FY27 will be intimated in due course. The notice was signed by Ajay Avinash Nadkarni, Vice President – Administration, Real Estate & Company Secretary, on September 25, 2026.

Compliance details

Item	Detail
Trading Window Closure Start	October 1, 2026
Trading Window Reopening	48 hours after results announcement
Reporting Period	Q2 and H1 FY27 (ended Sept 30, 2026)
Regulatory Framework	SEBI (Prohibition of Insider Trading) Regulations, 2015

Historical Stock Returns for GlaxoSmithKline Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.43%	+0.61%	-3.91%	+22.00%	+2.57%	+88.03%

How might the upcoming Q2FY27 results influence GlaxoSmithKline Pharmaceuticals' stock valuation relative to its current peer multiples?

What specific product segments within GSK's portfolio are analysts expecting to drive revenue growth in the second quarter of FY27?

Will the board meeting announcement trigger increased institutional trading activity once the window reopens 48 hours post-results?

GlaxoSmithKline Pharmaceuticals

View Company Insights

View All News

GSK Pharma shareholders approve Karine Natland appointment as non-executive director

1 min read | Published on 15 Sept 2026, 01:06 PM |Updated on 15 Sept 2026, 01:06 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Shareholders approved appointment of Karine Natland as non-executive director with 99.71% vote share
Bhushan Akshikar re-appointed as managing director with 99.71% shareholder approval
Promoter group cast all 127 million shares in favor of both resolutions
Total voter turnout stood at approximately 84.7% of eligible shares

*this image is generated using AI for illustrative purposes only.

GlaxoSmithKline Pharmaceuticals shareholders approved two ordinary resolutions via postal ballot on September 13, 2026. The votes confirmed the appointment of a new non-executive director and the re-appointment of the managing director.

The company conducted remote e-voting through KFin Technologies Limited from August 14, 2026, to September 13, 2026. P. N. Parikh of Parikh & Associates served as the scrutinizer for the process.

Voting Results

Shareholders voted overwhelmingly in favor of both resolutions. The promoter group, holding 127,054,524 shares, cast all its votes in favor of both appointments.

Resolution	Votes in Favor	Votes Against	Approval Rate
Appointment of Ms. Karine J F Natland	14,30,66,813	4,19,550	99.71%
Re-appointment of Mr. Bhushan Akshikar	14,30,25,237	415,465	99.71%

Ms. Karine J F Natland (DIN: 11870917) was appointed as a Non-Executive Director. Mr. Bhushan Akshikar (DIN: 09112346) was re-appointed as Managing Director.

Shareholder Participation

The total shares eligible for voting were 169,406,034. Approximately 84.7% of these shares were polled for both resolutions. Institutional holders participated actively, voting 97.45% in favor of Natland’s appointment and 97.46% in favor of Akshikar’s re-appointment.

What the Numbers Show

Promoter support was absolute, with 100% of the promoter group’s 127 million shares voting in favor. This contrasts with retail participation, where only 0.48% of public-other shares were polled, though those voted showed strong approval rates above 95%.

The voting results and scrutinizer report are available on the company website and the KFinTech portal. Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, certified the results.

Historical Stock Returns for GlaxoSmithKline Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.43%	+0.61%	-3.91%	+22.00%	+2.57%	+88.03%

How is the appointment of Ms. Karine J F Natland expected to influence GlaxoSmithKline's strategic direction in international markets or regulatory compliance?

What specific operational goals or performance metrics has Mr. Bhushan Akshikar outlined for his renewed tenure as Managing Director?

Given the low retail participation rate of 0.48%, what initiatives might the company implement to enhance engagement and voting turnout among public shareholders in future AGMs?

GlaxoSmithKline Pharmaceuticals

View Company Insights

View All News